Tools   Select Another Resource Report Type

http://mayoresearch.mayo.edu/mayo/research/biobank/index.cfm

A collection of blood samples and health information donated by volunteers, not focusing on any specific disease. Unlike many biobanks already in existence at Mayo Clinic and elsewhere, the Mayo Clinic Biobank is NOT focused on any particular disease. Rather, this biobank will collect samples and health information on patients and volunteers regardless of their health history. The only requirement is that they be 18 years of age or older, have a Mayo Clinic number, and be able to give informed consent. Once a participant becomes a part of the Biobank, they will be a part of ongoing health research conducted at Mayo Clinic indefinitely. The Biobank was established at Mayo Clinic, Rochester, and recruitment began in April of 2009. The goal of this project is to enroll 20,000 Mayo Clinic patients over the course of a three-year period in an effort to support a wide array of health-related research studies throughout the Institution.

Proper citation: Mayo Clinic Biobank (RRID:SCR_010723) Copy   

•   Source: SciCrunch Registry

http://www.lifelines.net/

Overall aim of the LifeLines Study is to unravel the interaction between genetic and environmental factors in the development of multifactorial diseases, their concurrent development in individuals and their complications as a complex trait. The LifeLines database contains questionnaire data, physical measurements and biological samples from different health examinations. Collaboration is encouraged as it helps to maximize the scientific value of the wealth of epidemiologic data made possible by the participation of more than 165,000 individuals in the LifeLines Cohort Study. Primary objectives of the LifeLines Cohort Study are: a. Which are the disease overriding risk factors which predict the development of a multifactorial disease during lifetime? b. How are these universal risk factors modified, or what determines the effect of a universal risk factor in an individual? Specific research questions will focus on risk factors and modifiers (genetic, environmental and combined or complex factors) for single and multiple diseases. In addition to co-morbidity, LifeLines focuses on co-determinants. The primary endpoints include measures of aging, metabolic and endocrine diseases, cardiovascular and renal diseases, pulmonary and musculoskeletal diseases, and psychopathology. Secondary aims include the assessment of the prevalence and incidence of multifactorial diseases, their risk factors and their treatment in individuals as well as in families. The burden of disease for the society will be quantified in terms of care needed, and total costs of care. Until November 3, 2011, almost 68,000 subjects have been included in the study. The 60,000th participant was screened in the beginning of September 2011. Recruitment rate at present is between 700 and 800 subjects per week. The laboratory measurements which are performed has changed. As of October 2011, LifeLines will continue to measure: hematologic parameters, including hemoglobin, white blood cells, platelets, WBC differentiation, blood glucose, cholesterol, HDL-cholesterol, triglycerides, serum creatinin and sodium/potassium. Liver enzymes, thyroid hormones, calcium, phosphate, albumin, uric acid and microalbuminuria will not be measured routinely. The samples that are available for almost all participants, are: # serum (taken either with or without gel separator) # EDTA plasma # citrate plasma # DNA # early morning urine sample # urine samples of 24-hour urine collection Any researcher who is member of an internationally recognized academic institution and who is interested in utilizing the research possibilities, data and materials of LifeLines may apply for access. The applicant who is acting as Principal Investigator must be connected to a department or institution with the competence to carry out the research project to term. A contract will give the right to use the data for a pre-determined period of time. This contract also comprises the costs for the LifeLines Biobank which the investigator needs to reimburse. To apply for access, refer to the electronic application process.

Proper citation: Lifelines Biobank (RRID:SCR_010730) Copy   

•   Source: SciCrunch Registry

http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/clinical-departments/pathology/research/oregon-brain-bank.cfm

Brain bank that harvests, banks and disperses postmortem tissue for use in brain and medical research. It also provides neuropathologic diagnoses of organic dementia in a cohort of NIH sponsored research subjects. The bank includes tissue primarily from patients with Alzheimer's but also includes Huntington's, Parkinson's, and other disorders.

Proper citation: Oregon Brain Bank (RRID:SCR_013085) Copy   

•   Source: SciCrunch Registry

http://www.flinders.edu.au/sabs/fcas/alsa/alsa_home.cfm

The general purpose of ALSA is to examine how social, biomedical, psychological, economic, and environmental factors are associated with age-related changes in the health and wellbeing of persons aged 70 years and older. The aim is to analyze the complex relationships between individual and social factors and changes in health status, health care needs and service utilization dimensions, with emphasis given to the effects of social and economic factors on morbidity, disability, acute and long-term care service use, and mortality. The study was designed to have common instrumentation with US studies. ALSA collected data from a random, stratified sample of all persons (both community and institution-dwelling) aged 70 years and older living in the metropolitan area of Adelaide, South Australia, using the State Electoral Database as the sampling frame. Spouses aged 65 and older and other household members aged 70 years and older also were invited to participate. The initial baseline data collection for ALSA began in September 1992 and was completed in March 1993. In the first wave, personal interviews were carried out for 2,087 participants, including 566 couples (that is, persons 70 years of age and over and their spouse, if 65 and over). Clinical assessments were obtained for 1,620 of the participants. Respondents were recontacted by telephone a year after initial interview (wave 2). The third wave of the study began in September 1994 and involved a complete reassessment, with a total of 1,679 interviews and 1,423 clinical assessments. To date, eleven waves of data have been collected, with the latest collection in May 2010, from 168 participants. Six of these waves were conducted via face-to-face interviews and clinical assessments, and five were telephone interviews. Future waves are planned, however are dependent on grant funding. Ancillary data collection has been ongoing since the initiation of the study, e.g., from secondary providers. Lists of ALSA participants are compared biannually with the agencies'' lists to determine the prevalence and incidence of receipt of services from these organizations. Another source of information has been the collection of data from the participants'' general practitioners about the respondent''s health status, history of services received, medication use, referrals to specialists, and current services provided. Baseline Sample Size: 2087 Dates of Study: 1992����������2010 (potentially ongoing) Study Features: * Longitudinal * International * Anthropometric Measures * Biospecimens Waves 1-5 (ICPSR), http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/06707 Wave 6 (ICPSR), http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/03679

Proper citation: ALSA - The Australian Longitudinal Study of Ageing (RRID:SCR_013146) Copy   

•   Source: SciCrunch Registry

http://www.nia.nih.gov/research/dab/aged-rodent-colonies-handbook

Colonies of barrier-raised, Specific Pathogen-Free (SPF) rodents under contractual arrangement with commercial vendors, specifically for use in aging research. They are not available for use as a general source of adult animals for unrelated areas of research. Animals from the NIA aged rodent colonies are available to investigators at academic and non-profit research institutions under the terms described on the Eligibility Criteria page. Orders must be submitted through the online rodent ordering system (ROS) (http://arc.niapublications.org/acb/stores/1/). Available strains: * Inbred Rats: Fischer 344 (F344), Brown Norway (BN) * Hybrid Rats: F344xBN F1 (F344BN); * Inbred Mice: BALB/cBy, CBA, C57BL/6, DBA/2 * Hybrid Mice: CB6F1 (BALB/cBy x C57BL/6), B6D2F1 (C57BL/6 x DBA/2) * Caloric Restricted Rats: F344 (males only), F344BN F1 (males only) * Caloric Restricted Mice: C57BL/6; B6D2F1 (males only)

Proper citation: NIA Aged Rodent Colonies (RRID:SCR_007317) Copy   

•   Source: SciCrunch Registry

http://jaxmice.jax.org/list/ra1642.html

Produce new neurological mouse models that could serve as experimental models for the exploration of basic neurobiological mechanisms and diseases. The impetus for the program resulted from the recognition that: * The value of genomic data would remain limited unless more information about the functionality of its individual components became available. * The task of linking genes to specific behavior would best be accomplished by employing a combination of different approaches. In an effort to complement already existing programs, the Neuroscience Mutagenesis Facility decided to use: a random, genome-wide approach to mutagenesis, i.e.N-ethyl-N-nitrosourea (ENU) as the mutagen; a three-generation back-cross breeding scheme to focus on the detection of recessive mutations; behavioral screens selective for the detection of phenotypes deemed useful for the program goals. The resulting mutant mouse lines have been available to the scientific community for the last five years and over 700 NMF mice have been sent to interested investigators for research; these mutant mouse lines will remain available as frozen embryos (which can be re-derived on request) and can be ordered through the JAX customer service at 1-800-422-6423 (or 207-288-5845). The results of the work of the Neuroscience Mutagenesis Facility and that of two other neurogenesis centers, i.e. The Neurogenomics Project at Northwestern University, and the Neuromutagenesis Project of the Tennessee Mouse Genome Consortium, can also be seen at Neuromice.org, a common web site of these three research centers; in addition, information about all mutants produced by these groups has been recorded in MGI.

Proper citation: JAX Neuroscience Mutagenesis Facility (RRID:SCR_007437) Copy   

•   Source: SciCrunch Registry

http://neurogenetics.nia.nih.gov

A suite of web-based open source software programs for clinical and genetic study. The aims of this software development in the Laboratory of Neurogenetics, NIA, NIH are * Build retrievable clinical data repository * Set up genetic data bank * Eliminate redundant data entries * Alleviate experimental error due to sample mix-up and genotyping error. * Facilitate clinical and genetic data integration. * Automate data analysis pipelines * Facilitate data mining for genetic as well as environmental factors associated with a disease * Provide an uniformed data acquisition framework, regardless the type of a given disease * Accommodate the heterogeneity of different studies * Manage data flow, storage and access * Ensure patient privacy and data confidentiality/security. The GERON suite consists of several self contained and yet extensible modules. Currently implemented modules are GERON Clinical, Genotyping, and Tracking. More modules are planned to be added into the suite, in order to keep up with the dynamics of the research field. Each module can be used separately or together with others into a seamless pipeline. With each module special attention has been given in order to remain free and open to the academic/government user., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: GERON (RRID:SCR_008531) Copy   

•   Source: SciCrunch Registry

http://165.124.81.52/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on January 08, 2013. A consortium of three facilities whose purpose is to establish, characterize, and distribute novel mutant mouse models with neural and/or behavioral phenotypes, and distribute them to the worldwide research community. Interested scientists are able to obtain information about mouse lines at all three sites in a single unified database. GOALS * Increase genomic and genetic tools for functional gene identification * Provide mice with mutations that alter the nervous system or behavior * Build collaborations between geneticists and neuroscientists The consortium is made up of three mutagenesis and phenotypic screening facilities, focused on identifying alterations in nervous system function and behavior, and established by NIH. They are the Neurogenomics Project at Northwestern University, the Neuroscience Mutagenesis Facility at The Jackson Laboratory, and the Neuromutagenesis Project of the Tennessee Mouse Genome Consortium. The NIH Neurogenomics Project at Northwestern University is directed by Dr. Joseph S. Takahashi, who also acts as the Director of the Neuromice.org consortium. Chemical mutagenesis is used to induce mutations throughout the genome and combined with phenotypic screens to detect mice with mutations. In order to maximize the genomic coverage and recover both dominant and recessive mutations, a dominant G1 screen and a recessive G3 screen are utilized. Phenotypic screens focus on five primary domains: learning and memory, behavioral responses to stress, responses to psychostimulants, circadian rhythmicity, and vision. The Neuroscience Mutagenesis Facility at the Jackson Laboratory is directed by Dr. Wayne N. Frankel. The Neuroscience Mutagenesis Facility is using a three-generation backcross breeding scheme to produce homozygous mutants and will thus recover dominant, semidominant, and recessive mutations. In addition, some mutagenesis will be done in ES cells followed by two generations of breeding. Phenotypic screens focus on identifying mutations affecting: motor function, seizure threshold, hearing, vision, and neurodevelopment. The Neuromutagenesis Project of the Tennessee Mouse Genome Consortium (TMGC) involves researchers throughout the state of Tennessee, under the direction of Dr. Daniel Goldowitz, Ph.D., at the University of Tennessee Health Science Center, Memphis. TMGC also includes researchers at Oak Ridge National Laboratory, Vanderbilt University, Meharry Medical College, University of Tennessee-Knoxville, St. Jude Children's Research Hospital, and the University of Memphis. The Project is using regional mutagenesis, covering regions on chromosomes 10, 14, 15, 19, and X, thus including approximately 15 of the genome in the screened region. Phenotypic screens include: motor and sensory function, learning and memory, neurohistology, aging, alcohol response, abused drug response, visual function, and social behavior. Neuromice.org has stopped taking orders online but mutants are orderable please contact the originating center for availability and pricing details. Live targeted mutant Fragile X model mice are now available for distribution.

Proper citation: neuromice (RRID:SCR_002993) Copy   

•   Source: SciCrunch Registry

http://coordinatingcenter.ucsf.edu/pride/

Randomized controlled trial being conducted at two clinical centers in the United States to learn more about the effects of weight loss on urinary incontinence. About 330 overweight women aged 30 or older will participate and will be followed for 18 months. Efficacy of weight reduction as a treatment for urinary incontinence will be examined at 6 months following the intensive weight control program, and the sustained impact of the intervention will be examined at 18 months. To increase the maintenance of weight reduction and facilitate evaluation of the enduring impact of weight loss on urinary incontinence, they propose to study a motivation-based weight maintenance program. At the end of the intensive weight control program, women randomized to the weight loss program will be randomized to either a 12-month skill-based maintenance intervention or to a motivation-based maintenance intervention. The maintenance interventions maximize the potential for sustained weight loss and will allow them to determine if long-term weight reduction will produce continued improvement in urinary incontinence.

Proper citation: Program to Reduce Incontinence by Diet and Exercise (RRID:SCR_009018) Copy   

•   Source: SciCrunch Registry

https://www.accordtrial.org/public

Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study.

Proper citation: ACCORD (RRID:SCR_009015) Copy   

•   Source: SciCrunch Registry

http://www.scienceexchange.com/facilities/tubingen-ageing-and-tumour-immunology-group-tati

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 19,2024. TATI is located at the Center for Medical Research (Zentrum fuer Medizinische Forschung, ZMF) within the University of Tuebingen Clinical School (Universitaetsklinikum Tuebingen) . We are engaged in immune monitoring (cancer immunotherapy, vaccination of elderly, Alzheimer) using 14-colour flow cytometry.

Proper citation: Tubingen Ageing and Tumour Immunology Group (RRID:SCR_012627) Copy   

•   Source: SciCrunch Registry

http://brainhealthregistry.org/

A website aimed at recruiting and assessing subjects for all types of neuroscience studies with the internet. The hope is to accelerate various types of observational studies and clinical trials, and also reduce costs. They are interested in having people, including healthy subjects of all ages, join the registry. Joining only takes a few minutes. The web-based project is designed to speed up cures for Alzheimer's, Parkinson's and other brain disorders. It uses online questionnaires and online neuropsychological tests (which are very much like online brain games).

Proper citation: Brain Health Registry (RRID:SCR_010230) Copy   

•   Source: SciCrunch Registry

http://scicrunch.org/Aging

Portal devoted to aging relevant scientific data and resources.

Proper citation: Aging Portal (RRID:SCR_000496) Copy   

•   Source: SciCrunch Registry

http://uwaging.org/genesdb/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on February 17,2023. A database of genes and interventions connected with aging phenotypes including those with respect to their effects on life-span or age-related neurological diseases. Information includes: organism, aging phenotype, allele type, strain, gene function, phenotypes, mutant, and homologs. If you know of published data (or your own unpublished data that you'd like to share) not currently in the database, please use the Submit a Gene/Intervention link.

Proper citation: Aging Genes and Interventions Database (RRID:SCR_002701) Copy   

•   Source: SciCrunch Registry

http://knightadrc.wustl.edu/

The Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) supports researchers and our surrounding community in their pursuit of answers that will lead to improved diagnosis and care for persons with Alzheimer disease (AD). The Center is committed to the long-term goal of finding a way to effectively treat and prevent AD. The Knight ADRC facilitates advanced research on the clinical, genetic, neuropathological, neuroanatomical, biomedical, psychosocial, and neuropsychological aspects of Alzheimer disease, as well as other related brain disorders.

Proper citation: Washington University School of Medicine Knight Alzheimers Disease Research Center (RRID:SCR_000210) Copy   

•   Source: SciCrunch Registry

http://lifespandb.sageweb.org/

Database that collects published lifespan data across multiple species. The entire database is available for download in various formats including XML, YAML and CSV.

Proper citation: Lifespan Observations Database (RRID:SCR_001609) Copy   

•   Source: SciCrunch Registry

http://www.physionet.org/

Collection of dissemination and exchange recorded biomedical signals and open-source software for analyzing them. Provides facilities for cooperative analysis of data and evaluation of proposed new algorithm. Providies free electronic access to PhysioBank data and PhysioToolkit software. Offers service and training via on-line tutorials to assist users at entry and more advanced levels. In cooperation with annual Computing in Cardiology conference, PhysioNet hosts series of challenges, in which researchers and students address unsolved problems of clinical or basic scientific interest using data and software provided by PhysioNet. All data included in PhysioBank, and all software included in PhysioToolkit, are carefully reviewed. Researchers are further invited to contribute data and software for review and possible inclusion in PhysioBank and PhysioToolkit. Please review guidelines before submitting material.

Proper citation: PhysioNet (RRID:SCR_007345) Copy   

•   Source: SciCrunch Registry

http://www.uky.edu/coa/ADC

Alzheimer's Disease Center that serves as the focal point for all Alzheimer's disease-related activities at the University of Kentucky and the Commonwealth of Kentucky providing an environment and core resources that catalyze innovative research, outreach, education, and clinical programs. Their ADC plans to build on its historic strengths and capitalize on emerging opportunities to provide an infrastructure that supports research designed to translate knowledge into therapeutic strategies for AD. They focus on two interrelated themes: Transitions and Translation. Their overall emphasis is to more effectively bridge the gap between basic research and clinical studies by facilitating translational efforts. They also carefully characterize transitions across the spectrum of cognitive impairment (normal/ preclinical AD/ MCI/ dementia), with focus on definition of early disease, and continue to support neuropathology as the bedrock of our center. The Alzheimer Disease Center's 2006-2011 grant award from the National Institute on Aging consists of five cores: * Administrative Core * Clinical Core * Biostatistics and Data Management Core * Neuropathology Core * Education & Information Transfer Core

Proper citation: University of Kentucky Alzheimer's Disease Center (RRID:SCR_008767) Copy   

•   Source: SciCrunch Registry

http://research.mssm.edu/cnic/

Center to advance research and training in mathematical, computational and modern imaging approaches to understanding the brain and its functions. Software tools and associated reconstruction data produced in the center are available. Researchers study the relationships between neural function and structure at levels ranging from the molecular and cellular, through network organization of the brain. This involves the development of new computational and analytic tools for imaging and visualization of 3-D neural morphology, from the gross topologic characteristics of the dendritic arbor to the fine structure of spines and their synapses. Numerical simulations of neural mechanisms based on these structural data are compared with in-vivo and in-vitro electrophysiological recordings. The group also develops new theoretical and analytic approaches to exploring the function of neural models of working memory. The goal of this analytic work is to combine biophysically realistic models and simulations with reduced mathematical models that capture essential dynamical behaviors while reproducing the functionally important features of experimental data. Research areas include: Imaging Studies, Volume Integration, Visualization Techniques, Medial Axis Extraction, Spine Detection and Classification, Applications of Rayburst, Analysis of Spatially Complex Structures, Computational Modeling, Mathematical and Analytic Studies

Proper citation: Computational Neurobiology and Imaging Center (RRID:SCR_013317) Copy   

•   Source: SciCrunch Registry

http://alzheimers.med.umich.edu/

An Alzheimer's disease center which aims to conduct and promote research on Alzheimer's disease and enhance public and professional understanding of dementia through education and outreach efforts. The MADC promotes clinical research on memory and aging which involves the direct use of research volunteers, biomarkers, and other clinical data collected through the University of Michigan Memory and Aging Project.

Proper citation: Michigan Alzheimer's Disease Center (RRID:SCR_008773) Copy   

•   Source: SciCrunch Registry